期刊
STROKE
卷 53, 期 5, 页码 1487-1499出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.122.038733
关键词
inflammation; ischemic stroke; microglia; thromboinflammation; thrombosis
资金
- European Union [777111]
- Deutsche Forschungsgemeinschaft (DFG) Walter Benjamin Program [DFG CA 2642/1-1]
- Forderprogramm der CoronaStiftung im Stifterverband
- DFG Forschungsgruppe [FOR 2879, 428778684]
- Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (FWO) [G0A8613, G078517, 1509216 N, G0E7620N]
- Katholieke Universiteit Leuven [OT/14/099, PDM/20/147, ISP/14/02L2]
- Queen Elisabeth Medical Foundation
- European Union's Horizon 2020 Research and Innovation Program INSIST [777072]
Despite years of research, ischemic stroke remains a major cause of death and disability globally. Thrombosis and inflammation are key factors in stroke, and this review provides an overview of recent studies on therapies currently undergoing clinical trials.
Despite decades of promising preclinical validation and clinical translation, ischemic stroke still remains as one of the leading causes of death and disability worldwide. Within its complex pathophysiological signatures, thrombosis and inflammation, that is, thromboinflammation, are highly interconnected processes leading to cerebral vessel occlusion, inflammatory responses, and severe neuronal damage following the ischemic event. Hence, we here review the most recent updates on thromboinflammatory-dependent mediators relevant after stroke focusing on recent discoveries on platelet modulation, a potential regulation of the innate and adaptive immune system in thromboinflammation, utterly providing a thorough up-to-date overview of all therapeutic approaches currently undergoing clinical trial.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据